Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 5Phase 2 4Phase 3 2Phase 4 1

Status

Terminated 3Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 383Carcinoma, Renal Cell 210Urinary Bladder Neoplasms 117Carcinoma, Non-Small-Cell Lung 99Melanoma 78Kidney Neoplasms 74Carcinoma, Transitional Cell 73Neoplasm Metastasis 72Ovarian Neoplasms 71Breast Neoplasms 69Neoplasms 64Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 50Stomach Neoplasms 49Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 39Lung Neoplasms 35Esophageal Neoplasms 32Non-Muscle Invasive Bladder Neoplasms 31Endometrial Neoplasms 30Carcinoma, Hepatocellular 29Sarcoma 28Small Cell Lung Carcinoma 25Head and Neck Neoplasms 25Colonic Neoplasms 19Wilms Tumor 15Metastatic Castration-resistant Prostate Cancer 14Glioblastoma 14Carcinoma, Merkel Cell 14

Interventions

tildrakizumab 1sabizabulin 1pembrolizumab 1enzalutamide 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Castration Resistant Prostate Cancer × Genitourinary × Clear all
NCT03177187 2024-09-26

ACE

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
30 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03752099 2023-09-26

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Veru Inc.

Phase 1/2 Terminated
80 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03658447 2023-07-28

PRINCE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Completed
37 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04486937 2020-07-27

mCRPC

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Phase 1/2 Unknown
90 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡